Advanced search
Publication Cover
Leukemia & Lymphoma Volume 50, 2009 - Issue 7
Submit an article Journal homepage
21
Views
0
CrossRef citations to date
0
Altmetric
Correspondence

Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma

Kristie A. Blum Division of Hematology–Oncology, Department of Internal Medicine, Arthur G. James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
,
Mehdi Hamadani Division of Hematology–Oncology, Department of Internal Medicine, Arthur G. James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
,
Gary S. Phillips Biostatical Core, Arthur G. James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
,
Gerard Lozanski Department of Pathology, The Ohio State University, Columbus, OH, USA
,
Amy J. Johnson Division of Hematology–Oncology, Department of Internal Medicine, Arthur G. James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
,
David M. Lucas Division of Hematology–Oncology, Department of Internal Medicine, Arthur G. James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
,
Lisa L. Smith Division of Hematology–Oncology, Department of Internal Medicine, Arthur G. James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
,
Robert Baiocchi Division of Hematology–Oncology, Department of Internal Medicine, Arthur G. James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
,
Thomas S. Lin Division of Hematology–Oncology, Department of Internal Medicine, Arthur G. James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
,
Pierluigi Porcu Division of Hematology–Oncology, Department of Internal Medicine, Arthur G. James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
,
Steven M. Devine Division of Hematology–Oncology, Department of Internal Medicine, Arthur G. James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
&
John C. Byrd Division of Hematology–Oncology, Department of Internal Medicine, Arthur G. James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
 show all
Pages 1232-1234 | Received 27 Apr 2009, Accepted 30 Apr 2009, Published online: 21 Jul 2009

References

  • Blum K A, Hamadani M, Philips G S, et al. Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory. aggressive non-Hodgkin lymphoma. Leuk Lymphoma 2009; 50: 349–356
  • Jeha S, Gandhi V, Chan K W, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004; 103: 784–789
  • Jeha S, Gaynon P S, Razzouk B I, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006; 24: 1917–1923
  • Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003; 102: 2379–2386
  • Kantarjian H M, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003; 21: 1167–1173
  • Kewalramani T, Zelenetz A D, Nimer S D, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103: 3684–3688
  • Martin A, Conde E, Arnan M, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 2008; 93: 1829–1836
  • Witzig T E, Geyer S M, Kurtin P J, et al. Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group. Leuk Lymphoma 2008; 49: 1074–1080
  • López A, Gutiérrez A, Palacios A, et al. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. Eur J Hematol 2008; 80: 127–132
  • Uy G L, Tomasson M H, Ruddell A, DiPersio J F, Vij R. The activity and toxicity of low dose clofarabine against relapsed or refractory myeloma. Haematologica 2006; 91: 1581–1582
  • Gandhi V, Plunkett W, Bonate P L, et al. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment. Clin Cancer Res 2006; 12: 4011–4017
  • Nabhan C, Fried W, Galvez W, Venugopal P, Gozun P, Bitran J. Phase I/II trial of clofarabine in refractory and/or relapsed non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 2008; 26: 8564, (abstr)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.